Medical Innovation Acceleration Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Medical Innovation Acceleration Act of 2025, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Agriculture, Immigration.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H7CC592F6249B443F886B42E67B523730: 1. Short title This Act may be cited as the Medical Innovation Acceleration Act of 2025.
- Section HD32CC5EDABAA4905BD47787E7D646146: 2. Exempting non-invasive diagnostic devices from regulation as devices Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)) is...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Medical Innovation Acceleration Act of 2025, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Agriculture, Immigration
Primary Purpose
This bill, Medical Innovation Acceleration Act of 2025, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeMr. Biggs of Arizona introduced the following bill; which was …
Referred to the House Committee on Energy and Commerce.
Introduced in House
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "federal_implementing_agencies"
- → Federal agencies assigned duties by the bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology